1. Home
  2. BLRX vs IGTA Comparison

BLRX vs IGTA Comparison

Compare BLRX & IGTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLRX
  • IGTA
  • Stock Information
  • Founded
  • BLRX 2003
  • IGTA 2021
  • Country
  • BLRX Israel
  • IGTA United States
  • Employees
  • BLRX N/A
  • IGTA N/A
  • Industry
  • BLRX Biotechnology: Pharmaceutical Preparations
  • IGTA Blank Checks
  • Sector
  • BLRX Health Care
  • IGTA Finance
  • Exchange
  • BLRX Nasdaq
  • IGTA Nasdaq
  • Market Cap
  • BLRX 54.1M
  • IGTA 44.2M
  • IPO Year
  • BLRX 2011
  • IGTA 2021
  • Fundamental
  • Price
  • BLRX $0.46
  • IGTA $11.39
  • Analyst Decision
  • BLRX Strong Buy
  • IGTA
  • Analyst Count
  • BLRX 2
  • IGTA 0
  • Target Price
  • BLRX $11.50
  • IGTA N/A
  • AVG Volume (30 Days)
  • BLRX 202.4K
  • IGTA 1.1K
  • Earning Date
  • BLRX 11-18-2024
  • IGTA 01-01-0001
  • Dividend Yield
  • BLRX N/A
  • IGTA N/A
  • EPS Growth
  • BLRX N/A
  • IGTA 11.48
  • EPS
  • BLRX N/A
  • IGTA 0.11
  • Revenue
  • BLRX $17,048,000.00
  • IGTA N/A
  • Revenue This Year
  • BLRX N/A
  • IGTA N/A
  • Revenue Next Year
  • BLRX N/A
  • IGTA N/A
  • P/E Ratio
  • BLRX N/A
  • IGTA $101.15
  • Revenue Growth
  • BLRX N/A
  • IGTA N/A
  • 52 Week Low
  • BLRX $0.44
  • IGTA $10.62
  • 52 Week High
  • BLRX $1.93
  • IGTA $11.73
  • Technical
  • Relative Strength Index (RSI)
  • BLRX 23.64
  • IGTA 74.45
  • Support Level
  • BLRX $0.50
  • IGTA $11.32
  • Resistance Level
  • BLRX $0.56
  • IGTA $11.35
  • Average True Range (ATR)
  • BLRX 0.05
  • IGTA 0.01
  • MACD
  • BLRX -0.01
  • IGTA 0.01
  • Stochastic Oscillator
  • BLRX 10.60
  • IGTA 88.89

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

About IGTA Inception Growth Acquisition Limited

Inception Growth Acquisition Ltd is a blank check company.

Share on Social Networks: